CANC Oncology ETF
5 Reasons to Consider
Impact
Innovation
Research Expertise
Growth
Uncorrelated
Impact
Innovation
Research Expertise
Growth
Uncorrelated
Fund Overview
Fund Details
As of December 6, 2023- Primary Exchange Nasdaq
- Ticker CANC
- Cusip 87975E701
- Median Bid/Ask Spread (30 Day) 0.3%
- Fund Inception Date August 14, 2023
- Gross Expense Ratio 0.99%
- Net Expense Ratio 0.75%
- Shares Outstanding 660,000
- Number of Holdings 48
- Investment Adviser Tema Global Limited
- Sub-Investment Adviser NEOS Investments, LLC
- Distributor Foreside Fund Services, LLC
- Portfolio Manager David K. Song, MD, PhD, CFA
Fund Summary
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals. The growing complexity of scientific discovery, regulation and a surge in investment opportunities requires expertise to navigate this exciting chapter in human development.Fund Documents
Portfolio Breakdown
Top 10 holdings
As of December 6, 2023- Company% Nav
Country Breakdown
Industry Breakdown
Fund Insights & Media

Tema launches actively managed oncology ETF: investing in the cancer life-science revolution
Prices & Performance
CANC
3 months
YTD
1 Year
3 Years
5 Years
Since Inception
As of November 30, 2023September 30, 2023
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.